Enrico Martin

177 Emerging therapeutic targets 16. Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus s tandard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18(6):812-822. doi:10.1016/S1470-2045(17)30334-0 17. Higham CS, Steinberg SM, Dombi E, et al. SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. Sarcoma. 2017;2017:8685638. doi:10.1155/2017/8685638 18. Kroep JR, Ouali M, Gelderblom H, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol Off J Eur Soc Med Oncol. 2011;22(1):207- 214. doi:10.1093/annonc/mdq338 19. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998;42(2):351-360. 20. Zehou O, Fabre E, Zelek L, et al. Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis. 2013;8:127. doi:10.1186/1750-1172-8-127 21. Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2006;107(5):1065- 1074. doi:10.1002/cncr.22098 22. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415-423. doi:10.1016/S1470- 2045(14)70063-4 23. Houghton PJ, Morton CL, Tucker C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007;49(7):928-940. doi:10.1002/ pbc.21078 24. Plowman J, Camalier R, Alley M, Sausville E, Schepartz S. US-NCI Testing Procedures. In: Feibig HhNT for C citations/Dickson et al. 2016. tx., Burger A, eds. Relevance of Tumor Models for Anticancer Drug Development. Basel: Karger; 1999:121- 135. 25. Torres KE, Zhu Q-S, Bill K, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011;17(12):3943-3955. doi:10.1158/1078-0432.CCR-11-0193 26. Ohishi J, Aoki M, Nabeshima K, et al. Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-beta. BMC Cancer. 2013;13:224. doi:10.1186/1471-2407-13-224 27. Ki DH, He S, Rodig S, Look AT. Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral ner ve sheath tumors. Oncogene. 2017;36(8):1058-1068. doi:10.1038/onc.2016.269 28. Wu LMN, Deng Y, Wang J, et al. Programming of Schwann Cells by Lats1/2- TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. Cancer Cell. 2018;33(2):292-308.e7. doi:10.1016/j.ccell.2018.01.005 29. Mo W, Chen J, Patel A, et al. CXCR4/ CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell. 2013;152(5):1077-1090. doi:10.1016/j. cell.2013.01.053 30. Lock R, Ingraham R, Maertens O, et al. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. J Clin Invest. 2016;126(6):2181- 2190. doi:10.1172/JCI85183 7